ARCX · IHE
+2.34% · +$2.33 · Vol Not reported
Live · updated 13:53:52 ET
IHE

iShares U.S. Pharmaceuticals ETF

$101.82
Card
Relationship Map

Follow $IHE

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $IHE by email

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D
Score not reportedVeridion does not publish a score-history trend for IHE until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
AI Analysis
Sovereign

Why is IHE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and available price action.
About iShares U.S. Pharmaceuticals ETF
Listed since
2006
Country
US
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$101.09
Day high
$102.74
Day low
$100.90
Previous close
$99.49
52W high
$108.16
-5.86% from high
52W low
$73.96
81% of range
Beta
-0.07
Shares out
15.4M
Avg volume
222.8K
VWAP
$99.49
Last session
Price history computed in-house
1W
+2.99%
1M
+0.92%
3M
+0.89%
1Y
+36.96%
YTD
+20.03%
SMA 50 $102.51 · below
SMA 200 $93.68 · above
52W position 81%

IHE overview

Financials
Company financial statements are not applicable for IHE.
Public disclosures

Congress activity in IHE

3 filers · 1 buys · 3 sells (0 labeled S (partial)) · Feb 4, 2015 to Jan 31, 2018 · House 2 / Senate 2

All available history · Latest 1 of 4 lines · Read Oct 15, 2026, 5:57 PM UTC

Federal contracts

IHE contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IHE in this window.
Lobbying spend

IHE lobbying filings, year to date.

Registered lobbying filings matched to iShares U.S. Pharmaceuticals ETF.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IHE in this window.
Analyst ratings
Sovereign unlock shows available analyst consensus for IHE.
Veridion by email

Disclosure findings, methodology notes, and product updates when we have them. No fixed schedule yet. No advertising list resale.